首页> 外文OA文献 >Nivolumab versus docetaxel in a predominantly Chinese patient population with previously treated advanced non-small cell lung cancer: 2-year follow-up from a randomized, open-label, phase 3 study (CheckMate 078)

【2h】

Nivolumab versus docetaxel in a predominantly Chinese patient population with previously treated advanced non-small cell lung cancer: 2-year follow-up from a randomized, open-label, phase 3 study (CheckMate 078)

机译：Nivolumab与多西紫杉醇在主要的中国患者人口中，具有先前治疗的晚期非小细胞肺癌：从随机，开放标签，第3阶段研究的2年随访（Checkmate 078）

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
相似文献
相关主题

著录项

作者
Shun Lu; Jie Wang; Ying Cheng; Tony Mok; Jianhua Chang; Li Zhang; Jifeng Feng; Hai-Yan Tu; Lin Wu; Yiping Zhang; Alexander Luft; Jian-ying Zhou; Zhiyong Ma; You Lu; Chengping Hu; Yuankai Shi; Kejing Ying; Hua Zhong; Elena Poddubskaya; Ross A Soo; Yee Hong Chia; Ang Li; Amy Li; Yi-Long Wu;
展开▼
作者单位

展开▼
年度 2021
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Nivolumab Versus Docetaxel in Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer: Two-Year Outcomes From Two Randomized, Open-Label, Phase III Trials (CheckMate 017 and CheckMate 057) [J] . Horn Leora, Spigel David R., Vokes Everett E., Journal of Clinical Oncology . 2017,第35期

机译：Nivolumab对先前治疗的非小细胞肺癌患者的多西紫杉醇：两年随机，开放标签，第III期试验的两年成果（Checkmate 017和Checkmate 057）
2. Nivolumab Versus Docetaxel in a Predominantly Chinese Patient Population With Previously Treated Advanced NSCLC: CheckMate 078 Randomized Phase III Clinical Trial [J] . Wu Yi-Long, Lu Shun, Cheng Ying, Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer . 2019,第5期

机译：Nivolumab与多西紫杉醇在主要的中国患者人口中，具有先前治疗的高级NSCLC：Checkmate 078随机期III临床试验
3. Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group. [J] . Fossella FV, DeVore R, Kerr RN, Journal of Clinical Oncology . 2000,第12期

机译：多西他赛与长春瑞滨或异环磷酰胺在之前接受过含铂化疗方案治疗的晚期非小细胞肺癌患者中的随机III期试验。 TAX 320非小细胞肺癌研究组。
4. Pemetrexed versus docetaxel single agent chemotherapy in chemotherapy-naive elderly patients with advanced non-small cell lung cancer [C] . Hua Xin, Zhenguo Han, Haibo Huang 2011 International Conference on Human Health and Biomedical Engineering . 2011

机译：培美曲塞与多西他赛单药化疗在未接受化疗的老年晚期非小细胞肺癌患者中的作用
5. Symptoms Leading to Nutritional Risk in Advanced Non-Small Cell Lung Cancer Patients: The Importance of Nutritional Screening in the Advanced Lung Cancer Population [D] . Swinton, Nelda. 2009

机译：导致晚期非小细胞肺癌患者营养风险的症状：在晚期肺癌人群中进行营养筛查的重要性
6. Nivolumab Versus Docetaxel in Previously Treated Patients With Advanced Non–Small-Cell Lung Cancer: Two-Year Outcomes From Two Randomized Open-Label Phase III Trials (CheckMate 017 and CheckMate 057) [O] . Leora Horn, David R. Spigel, Everett E. Vokes, -1

机译：在接受过治疗的晚期非小细胞肺癌患者中Nivolumab与多西他赛的比较：两项随机开放标签III期试验（CheckMate 017和CheckMate 057）的两年结果
7. PCN123 HEALTH CARE RESOURCE UTILIZATION (HCRU) OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) TREATED WITH NIVOLUMAB VERSUS DOCETAXEL: RESULTS FROM THE CHECKMATE 078 (CM078) TRIAL [O] . R. Lawrance, M. DeRosa, F. Taylor, 2019

机译：用Nivolumab治疗的先进非小细胞肺癌（NSCLC）的PCN123患者的医疗资源利用（HCRU）与多元紫杉醇：Checkmate 078（CM078）试验结果

Nivolumab versus docetaxel in a predominantly Chinese patient population with previously treated advanced non-small cell lung cancer: 2-year follow-up from a randomized, open-label, phase 3 study (CheckMate 078)

著录项

相似文献

相关主题

期刊订阅